Hemolink may not beat placebo

Hemosol (TSE:HML) said that in a preliminary analysis of a U.K.-Canadian Phase III trial of its Hemolink crosslinked hemoglobin 10 percent solution to reduce use of donor blood in coronary artery bypa...